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EDITORIAL
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P. Selby
Department ofClinical Medicine, University ofLeeds, St James's University Hospital, Beckett Street, Leeds LS9 7TF, UK.
In this issue we publish two papers which focus particularly
on issues relating to the provision of the Health Service in
the United Kingdom. Michael Richards and colleagues ad-
dress the use of resources and cost implications for the care
of patients' advanced breast cancer (Richards et al., 1993).
They seek to describe the costs in the UK and compare them
to earlier work published in relation to advanced breast
cancer in other countries (de Koning et al., 1992; Hurley et
al., 1992). Their results certainly show a striking similarity to
the costs described in The Netherlands by de Koning and
colleagues (1992). As Richards et al. point out, all costing
estimates involve making assumptions and are subject to
error and often criticism. In the UK Health Service at the
moment standard tariffs for use in costing studies and com-
parison of treatments are not available although they are
being developed as part of the NHS Reform. In another
paper Malcom McIllmurray and colleagues describe the
development of a cancer support organisation, CancerCare,
in North Lancashire and South Lakeland (Mclllmurray et
al., 1993). In describing the use of relaxation therapy and
high demand for it they draw attention to important issues
that need to be addressed by the providers of heath care in
the UK.
These papers address Service issues. They reflect an in-
creasing interest in research into the quality of health care
provision and its costs. These issues have importance across
the world as advocates of expensive developments in health
care are confronted by economic constraints. In the United
Kingdom, research into optimal provision of health care has
been brought to increasing prominence by the National
Health Service Research and Development initiative led by
Professor Michael Peckham (1991).
The evaluation of any health care intervention is a proper
subject for research and is of considerable interest to the
British Journal of Cancer. In our earlier articles on editorial
policy (Selby, 1991; Twentyman & Selby, 1991a and b) we
emphasised our commitment to the publication of high
quality research into the provision of care particularly when
it draws on sound methodological approaches including ran-
domised prospective trials. A formal economic evaluation
will include an appraisal both of inputs (costs) and the
outputs in terms of patient well-being and survival. Careful
measurement of survival output, remission status, toxicity
and quality of life have been emphasised for many years and
the current difficulties in the scientific evaluation of quality of
life were brought out in the report of the Medical Research
Council's Working Party on quality of life in cancer patients
(Maguire & Selby, 1989). Formal economic evaluation has
been less explored scientifically. There is however a growing
literature on the economics of health care ranging from
outpatient chemotherapy (Calman et al., 1978) to the costs
and benefits of screening programmes (Moskowitz, 1987;
Tuck et al., 1989). The subject has recently been reviewed for
a general oncology audience by Goddard & Drummond
(1991) and methodology in relation to good economic app-
raisal of health care programmes has been described by
Drummond (1980) and Drummond et al. (1988).
The issues involved in scientific evaluation of the economic
implications of cancer care are certainly complex for the
non-economist. Inputs into health care must taken account
not only of the direct costs of providing treatment (familiar
issues like the cost of radiotherapy and chemotherapy and
length of stay in hospital) but also indirect costs arising from
loss of time at work. Other costs may be difficult to define
arising from the anxiety and distress generated both for
patients and for their families. The impact of treatment will
also influence the economic productivity of younger cancer
patients and for some purposes it may be appropriate to
consider this factor. Goddard & Drummond (1991) point out
this may bias resource allocation towards health care pro-
grammes affecting the economically active sector of the
population unless caution is used in interpreting the results.
Sometimes economic appraisal may be simplified by the
demonstration that treatments have equivalent efficacy and
then estimations of cost may be sufficient. However, con-
sidering quality of life in addition to survival will be essential
in determining equivalent treatment efficacy.
It is attractive to link economic evaluation to the most
clearly evaluated clinic.al data which is that produced in
randomised controlled clinical trials. This attractive proposi-
tion is being pursued in a number of trials currently but does
present some methodological challenges (Goddard & Drum-
mond, 1991). If the trial practice differs from routine practice
then cost data collected during trials may not be relevant to
subsequent clinical practice. Multi-centre trials will often
involve a number of countries where cost implications may
differ and the need for economic evaluation may alter the
patient numbers required for adequate statistical power in a
trial.
Full evaluation of cancer care is a very important area of
research and requires careful application and further develop-
ment of appropriate methods both in clinical trials and in
clinical practice. Extensive collaboration between clinicians
and economists will be necessary if Health Services, and
ultimately patients, are to benefit from these approaches.
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